QED Clinical Services Ltd (“QED”) is a ground-breaking Clinical Research Organisation (CRO), focused on the provision of quality clinical services. We operate across the various phases of the clinical development spectrum (phases I – IV) in numerous therapeutic areas (including oncology, CNS, cardiology, immunology and metabolic disorders) and across multiple Continents (including “emerging” regions such as Russia, India and China).

We pride ourselves on delivering a highly innovative, flexible and cost effective clinical outsourcing solution to customers, of all sizes, via our unique but proven franchising approach.

With a presence in more than 25 countries, globally we can provide a superior quality tailored service in areas such as Clinical Monitoring, Regulatory Support and Project Management at an extremely competitive rate.

In addition to this widespread geographical coverage, our approach allows our customers to benefit from high quality consistency under the QED brand, without the large overhead costs associated with CROs of similar or larger size.

With considerably lower than CRO industry average turnover rates for clinical staff, QED’s structure makes us an ideal Functional Service Provider (FSP), helping to guarantee consistency across entire development programmes. Equally so, with more than 250 clinical personnel we can give our customers access to and more importantly choice from a wealth of highly experienced and focused team members on a global basis for individual clinical projects.

Our mission:

To be recognised as the most progressive company in the CRO industry by providing intelligent and innovative global solutions to our sponsors. With the heart of our business; our highly experienced and motivated personnel, guided by our resolute commitment to quality we will enhance the drug development process for our sponsors and ultimate benefit of patients.

Our objective:

QED’s overarching objective is to ensure that the development journey of our sponsor’s drug – its fantastic voyage- is completed successfully, on time and on budget. Only then can we rest safe in the knowledge that the outcome has been successful, with the drug reaching the market place as swiftly and efficiently as possible.
Our highly experienced and motivated team, backed by our resolute commitment to quality will enhance this drug development process for the benefit of all. We undertake our mission with dedication to flexibility, operational excellence and cost effectiveness.

Our Customer focus:

QED help our pharmaceutical and biotechnology sponsors achieve their goals by treating every customer and every project, no matter how big or small, as if it were our own. We appreciate the huge investment made in R&D activities and share in the drive to make it a success. We are able to do this because of our highly focused approach and absolute critical emphasis we place on the provision of superior quality service to all our sponsors, regardless of their size.
QED understands that when a sponsor is looking for a CRO partner, they need to be confident their chosen provider can and will deliver. QED is that partner.

Our Core Team:

Thomas Ogorka
Managing Director

As Managing Director, Thomas provides the vision and leadership which has been fundamental to QED’s growth since the company was founded in 2002. He has over 15 years experience in the global pharmaceutical and CRO industry. Prior to founding QED, Thomas has been involved in setting up a CRO in Germany and worked for a top 5 global CRO and for a Central Laboratory at various Business Development levels.

Nazira Maruf
Head of Clinical Operations

As Head of Clinical Operations, Nazira is accountable for the successful delivery of all projects for QED. She is also responsible for the effective resourcing of studies and management of personnel. With extensive experience in clinical research developed over 16 years, in both the pharmaceutical and CRO environments, Nazira joined QED in 2003 and has held various positions as the company has grown from Senior CRA, Clinical Resource Manager to her current position as Head of Clinical Operations.

Paul Thompson
Director Business Development

As Director Business Development, Paul is responsible for the definition of QED’s business development strategy to support the identification and procurement of global business and to drive growth of the company. He has over 7 years experience in business development and account management and joined QED in 2007. Prior to joining QED, Paul held positions of increasing responsibility within contracts, proposal and business development for a major top 4 CRO, over a period of 5 years. He has also worked successfully in an account management capacity for a US Fortune 500 major Information Technology corporation.

Rajmattie Mangroo
Business Administration Manager

As Business Administration Manager, Raj is responsible for the administration of QED projects and ensures that the operations of our company run efficiently with support of QED's ERP systems. Raj joined QED in 2006 after having worked at the London Stock Exchange for a major bank.